Analysis

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis

Protagonist Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to PTGX.

websitePTGX/analysis/PTGX

Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to PTGX.

Stock profile

Ticker

PTGX

Asset type

Stock

Market cap

$7.26B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Protagonist Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • PTGX primary listing
  • PGF

Latest Protagonist Therapeutics, Inc. news

Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in poly...

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and ...

Protagonist Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)

Protagonist Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia

Research sections

Valuation

Review valuation context for Protagonist Therapeutics, Inc..

Future growth

Review future growth context for Protagonist Therapeutics, Inc..

Past performance

Review past performance context for Protagonist Therapeutics, Inc..

Financial health

Review financial health context for Protagonist Therapeutics, Inc..

Dividend

Review dividend context for Protagonist Therapeutics, Inc..

Management

Review management context for Protagonist Therapeutics, Inc..

Ownership

Review ownership context for Protagonist Therapeutics, Inc..

Other information

Review other information context for Protagonist Therapeutics, Inc..

Community

Review community context for Protagonist Therapeutics, Inc..